201 related articles for article (PubMed ID: 37603060)
21. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
Reikvam H; Tiu RV
Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463
[TBL] [Abstract][Full Text] [Related]
22. Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia.
Squizzato A; Romualdi E; Passamonti F; Middeldorp S
Cochrane Database Syst Rev; 2013 Apr; (4):CD006503. PubMed ID: 23633335
[TBL] [Abstract][Full Text] [Related]
23. The relationship between factor V Leiden, prothrombin G20210A, and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia.
Trifa AP; Cucuianu A; Popp RA; Coadă CA; Costache RM; Militaru MS; Vesa ŞC; Pop IV
Ann Hematol; 2014 Feb; 93(2):203-9. PubMed ID: 23828072
[TBL] [Abstract][Full Text] [Related]
24. Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis.
Alvarez-Larrán A; Pereira A; Magaz M; Hernández-Boluda JC; Garrote M; Cuevas B; Ferrer-Marín F; Gómez-Casares MT; García-Gutiérrez V; Mata-Vázquez MI; Turon F; Hernandez-Gea V; Arellano-Rodrigo E; Cervantes F; García-Pagán JC;
Ann Hematol; 2020 Apr; 99(4):791-798. PubMed ID: 32086587
[TBL] [Abstract][Full Text] [Related]
25. [State-of-the-art management for essential thrombocythemia and polycythemia vera].
Sugimoto Y
Rinsho Ketsueki; 2021; 62(8):1050-1059. PubMed ID: 34497191
[TBL] [Abstract][Full Text] [Related]
26. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
27. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance.
Chiaranairungrot K; Kaewpreechawat K; Sajai C; Pagowong N; Sukarat N; Piriyakhuntorn P; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L; Rattarittamrong E
Hematology; 2022 Dec; 27(1):813-819. PubMed ID: 35894859
[TBL] [Abstract][Full Text] [Related]
29. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
[TBL] [Abstract][Full Text] [Related]
30. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms.
Duchemin J; Ugo V; Ianotto JC; Lecucq L; Mercier B; Abgrall JF
Thromb Res; 2010 Sep; 126(3):238-42. PubMed ID: 20656333
[TBL] [Abstract][Full Text] [Related]
31. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
32. Thrombosis and risk factors in female patients with a rare acquired thrombophilia: chronic myeloproliferative disorder - polycythaemia vera and essential thrombocythaemia.
Pósfai É; Marton I; Kiss-László Z; Kotosz B; Széll M; Borbényi Z
Eur Rev Med Pharmacol Sci; 2014; 18(24):3810-8. PubMed ID: 25555871
[TBL] [Abstract][Full Text] [Related]
33. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia.
Hernández-Boluda JC; Arellano-Rodrigo E; Cervantes F; Alvarez-Larrán A; Gómez M; Barba P; Mata MI; González-Porras JR; Ferrer-Marín F; García-Gutiérrez V; Magro E; Moreno M; Kerguelen A; Pérez-Encinas M; Estrada N; Ayala R; Besses C; Pereira A;
Ann Hematol; 2015 Jun; 94(6):911-8. PubMed ID: 25680896
[TBL] [Abstract][Full Text] [Related]
34. Myocardial infarction as a thrombotic complication of essential thrombocythemia and polycythemia vera.
Pósfai É; Marton I; Borbényi Z; Nemes A
Anatol J Cardiol; 2016 Jun; 16(6):397-402. PubMed ID: 27182615
[TBL] [Abstract][Full Text] [Related]
35. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
36. Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.
Kamiunten A; Shide K; Kameda T; Sekine M; Kubuki Y; Ito M; Toyama T; Kawano N; Marutsuka K; Maeda K; Takeuchi M; Kawano H; Sato S; Ishizaki J; Akizuki K; Tahira Y; Shimoda H; Hidaka T; Yamashita K; Matsuoka H; Shimoda K
Int J Hematol; 2018 Jun; 107(6):681-688. PubMed ID: 29488167
[TBL] [Abstract][Full Text] [Related]
37. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
Mulas O; Caocci G; Stagno F; Bonifacio M; Annunziata M; Luciano L; Orlandi EM; Abruzzese E; Sgherza N; Martino B; Albano F; Galimberti S; Pregno P; Bocchia M; Castagnetti F; Tiribelli M; Binotto G; Gozzini A; Capodanno I; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; De Gregorio F; Elena C; Trawinska MM; Cattaneo D; Attolico I; Baratè C; Pirillo F; Sicuranza A; Gugliotta G; Stella R; Scalzulli E; Iurlo A; Foà R; Breccia M; La Nasa G
Ann Hematol; 2020 Jul; 99(7):1525-1530. PubMed ID: 32474619
[TBL] [Abstract][Full Text] [Related]
38. Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Leone G; Barbui T;
Am J Hematol; 2010 Feb; 85(2):97-100. PubMed ID: 20052743
[TBL] [Abstract][Full Text] [Related]
39. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
40. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
Panova-Noeva M; Marchetti M; Buoro S; Russo L; Leuzzi A; Finazzi G; Rambaldi A; Ottomano C; Ten Cate H; Falanga A
Blood; 2011 Sep; 118(9):2599-601. PubMed ID: 21750318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]